Johnson & Johnson’s JNJ-5120, a depression program developed with Contineum Therapeutics, missed its primary endpoint in a Phase 2 trial. The failure further complicates the outlook for the partnered asset and narrows the near-term path for new treatment options in a crowded depression landscape. The report centers on the missed endpoint itself, with details on magnitude and secondary outcomes not provided in the available excerpt. For investors and partners, the key takeaway is the additional readthrough risk introduced by another Phase 2 lapse.